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Abstract
Emerging evidence that an elevated serum gamma-glutamyltransferase (GGT) level is
associated with an increased risk of gastrointestinal cancer, but still controversial. The aim
of this study to assess the relationship between GGT level and risk of gastrointestinal can-
cer, and the contribution of the interaction of hyperglycemia with elevated GGT level to the
incidence of gastrointestinal cancer by the stratified analysis. A total of 8,120,665 Koreans
who received medical checkups in 2009 were included. Subjects were classified according
to the quartile of GGT level for women and men. The incidence rates of gastrointestinal can-
cer for each group were analyzed using Cox proportional hazards models. During follow-up,
129,853 cases of gastrointestinal cancer newly occurred (esophagus, 3,792; stomach,
57,932; and colorectal, 68,789 cases). The highest GGT quartile group showed an
increased risk of gastrointestinal cancer (esophagus, hazard ratio = 2.408 [95% confidence
interval, 2.184–2.654]; stomach, 1.121 [1.093–1.149]; and colorectal, 1.185 [1.158–1.211]).
The risk increased significantly with the rise in GGT quartile level, regardless of the site of
cancer. The stratified analysis according to glycemic status showed that the effect of ele-
vated GGT was predominant in the risk of esophageal cancer. The effect of elevated GGT
further increased the risk of stomach and colorectal cancers in diabetic patients. An elevated
level of GGT was associated with an increased risk of gastrointestinal cancer, regardless of
the site of cancer. The effect of the increase in GGT level on the risk of gastrointestinal can-
cer depended on the type of cancer and glycemic status.
Introduction
Serum gamma-glutamyltransferase (GGT) is an indicator related to hepatic dysfunction and
used as a surrogate marker that reflects excessive alcohol consumption [1, 2]. Several epidemi-
ologic studies have reported that elevated GGT level is associated with the incidence of various
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disease including metabolic syndrome, diabetes mellitus (DM), and cardiovascular disease [3–
9]. Emerging evidence indicates that an elevated GGT level is also linked to increased risk of
cancer. Notably, many studies have demonstrated a positive correlation between an elevated
GGT level and the risk of gastrointestinal cancer, but results have been inconsistent depending
on sex and the site of cancer [10–16]. Hence, further study with a large population is needed to
establish any association between elevated GGT level and risk of gastrointestinal cancer.
Diabetes mellitus is a chronic disease of increasing prevalence, generally accompanied by
hyperglycemia caused by insulin resistance [17]. An elevated GGT level is related to hypergly-
cemia, and many studies have reported that patients with DM have an increased risk of gastro-
intestinal cancer [18–24]. However, few studies have assessed the association of serum GGT
level and glycemic status with the incidence of gastrointestinal cancer in the general popula-
tion, and little is known about whether the effect of GGT on the gastrointestinal cancer risk is
influenced by glycemic status.
Therefore, we aimed to assess whether an elevated serum GGT level is associated with the
risk of gastrointestinal cancer through a large-scale study using nationwide data. In addition,
we evaluated the effect of glycemic status on the association between an elevated GGT level
and the risk of gastrointestinal cancer, and the contribution of the interaction between these
two factors on the incidence of gastrointestinal cancer.
Materials and methods
Data sources
This population-based study was retrospectively conducted using the database from the
National Health Insurance Service (NHIS) in South Korea. The NHIS is one of the social secu-
rity systems provided by the government, and all Koreans are obliged to enroll in. It serves to
pay health care providers for medical services on behalf of the general population. All data
related to the medical services guaranteed by the NHIS are stored in this database. The NHIS
database collects demographic data as well as the information regarding medical services,
including medications, hospitalization, and diagnoses identified by the International Classifi-
cation of Disease, Tenth Revision (ICD-10) codes of the subscribers. The NHIS recommends
that subscribers undergo a general medical check-up biennially. This general medical check-
up includes body measurements, chest X-ray, and blood chemistry tests.
Data collection and study population
Demographic information including age, sex, and income was stored in the NHIS database for
all participants who underwent general medical checkups. The weight, height, and blood pres-
sure for participants were measured, and laboratory tests including fasting blood glucose
(FBG), aspartate aminotransferase, alanine aminotransferase, GGT level, and cholesterol were
performed on the same day. Body mass index (BMI) was calculated by dividing the weight
(kg) by height squared (m2). A self-reporting questionnaire was used to assess drinking habits,
history of smoking, income, and exercise habits for the participants. The history of smoking
was classified into three categories: (1) non-smoker; (2) ex-smoker; and (3) current smoker.
An ex-smoker was defined as a person with smoking experience of>100 cigarettes, although
smoking had currently ceased. A heavy drinker was defined as a person drinking >30 g of
alcohol per week.
Adults over the age of 20 years who underwent a general medical check-up provided by the
NHIS during January–December 2009 qualified for registration in this cohort. At the time of
enrolment, patients who were previously diagnosed with cancer identified by ICD-10, regard-
less of the type, were excluded. To minimize disruption of pre-existing factors to the incidence
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of gastrointestinal cancer, any type of cancer patients who were diagnosed within one year of
the time of enrolment were excluded from the cohort. Individuals diagnosed with liver cirrho-
sis (K703) or hepatitis (K746) were also excluded. To avoid the confounding effect of excessive
alcohol consumption on the serum GGT level, individuals with heavy drinking were excluded
from the cohort.
Outcomes and ethical considerations
Since there might be a variability of GGT levels depending on measurement equipment and
no threshold was reported to be associated with an increased risk of gastrointestinal cancer,
subjects in the cohort were divided into four groups according to the quartile level of GGT.
The quartile level of GGT was differently determined, considering differences in the level of
GGT by sex (men: first quartile [Q1], <21 U/L; second quartile [Q2], 21–29 U/L; third quartile
[Q3], 30–47 U/L; and fourth quartile [Q4],�48 U/L; and women: Q1,<13 U/L; Q2, 13–15 U/
L; Q3, 16–22 U/L; and Q4,�23 IU/L). The primary outcome was to evaluate the incidence
rate of gastrointestinal cancer for each group by the quartile level of GGT. The secondary out-
come was indirectly to assess the interaction of an elevated GGT level and hyperglycemia con-
tributing to the risk of gastrointestinal cancer, using stratified analysis according to glycemic
status. The glycemic status was categorized in accordance with FBG (non-DM, FBG< 100
mg/dL; impaired fasting glucose (IFG), 100� FBG < 126 mg/dL; and DM, FBG� 126 mg/
dL). The follow-up was terminated at the occurrence of gastrointestinal cancer and monitoring
of other members of the cohort was continued to until 31 December 2017. The gastrointestinal
cancer included esophageal, stomach, and colorectal cancers. Cases of newly diagnosed gastro-
intestinal cancer during the follow-up period were identified using ICD-10 codes in the NHIS
database as follows–esophageal (C15), stomach (C16), and colorectal cancer (C18–20)–and
their index date was the first day that cancer was recorded. This study was approved by the
Institutional Review Board at Seoul National University Hospital. All data were fully anon-
ymized before we access them, so the requirement for informed consent was waived. (IRB
approved data: 2019.06.07, No. of IRB: E-1906-008-1036).
Statistical analysis
Data were expressed as mean ± standard deviation for continuous variables and as number
and proportions for categorical variables. To compare differences among groups, one-sided
ANOVA were used for continuous data and the chi-square test for categorical data. The inci-
dence rate of gastrointestinal cancer was calculated by dividing the number of incident cases
by the overall follow-up period and presented as 10,000 person-years. The Cox proportional
hazard model was used to evaluate the association GGT level and risk of gastrointestinal can-
cer. In addition, stratified analyses were conducted according to glycemic status. Two adjust-
ment models were applied, model 1 was adjusted for age and sex, and model 2 was adjusted
for age, sex, BMI, smoking, drinking, exercise, and income which were known to be risk fac-
tors for gastrointestinal cancer. A statistical significance was defined as P< 0.05. Statistical
analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
A total of 8,120,665 individuals were enrolled in this cohort. The selection process for the
study subjects is illustrated in Fig 1. The eligible population was categorized into four groups
by the quartile level of serum GGT. The baseline characteristics of the population in
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accordance with GGT quartiles are presented in Table 1. Compared with the lower GGT quar-
tile groups (Q1–3), more individuals who drank or smoked were included in the higher GGT
quartile group (Q4). The proportion of subjects with hypertension, dyslipidemia, and
Fig 1. Flow chart of selection process of study subject.
https://doi.org/10.1371/journal.pone.0245052.g001
Table 1. Baseline characteristics by serum GGT level (n = 8,120,665).
GGT quartile P-value
Q1 Q2 Q3 Q4
N = 2,001,551 N = 2,029,189 N = 2,099,258 N = 1,990,667
Age (years)� 43.75 ± 14.75 45.93 ± 14.36 47.87 ± 13.83 49.28 ± 12.9 < .0001
Sex, Men (%) 1,047,272 (52.32) 1,026,998 (50.61) 1,105,896 (52.68) 1,054,248 (52.96) < .0001
Waist circumference (cm)� 76.34 ± 8.1 78.36 ± 8.66 80.92 ± 8.91 83.5 ± 8.88 < .0001
Body mass index (kg/m2)� 22.37 ± 2.71 23.1 ± 2.96 24.02 ± 3.16 24.97 ± 3.34 < .0001
Exercise (%) 1,036,622 (51.79) 1,044,128 (51.46) 1,074,483 (51.18) 1,000,684 (50.27) < .0001
Smoking status (%) < .0001
Non-smoker 1,330,105 (66.45) 1,308,008 (64.46) 1,272,410 (60.61) 1,140,435 (57.29)
Ex-smoker 259,333 (12.96) 269,649 (13.29) 294,621 (14.03) 261,707 (13.15)
Current smoker 412,113 (20.59) 451,532 (22.25) 532,227 (25.35) 588,525 (29.56)
Low income (%) 425,064 (21.24) 429,320 (21.16) 440,156 (20.97) 425,771 (21.39) < .0001
Drinker (%) 783,461 (39.14) 876,698 (43.2) 997,037 (47.49) 1,060,510 (53.27) < .0001
Hypertension (%) 290,349 (14.51) 403,676 (19.89) 564,871 (26.91) 713,722 (35.85) < .0001
Dyslipidemia (%) 165,360 (8.26) 272,186 (13.41) 420,969 (20.05) 577,006 (28.99) < .0001
Metabolic syndrome (%) 218,539 (10.92) 371,250 (18.3) 607,707 (28.95) 869,756 (43.69) < .0001
Fasting glucose (mg/dl)� 92.13 ± 16.49 94.07 ± 18.82 97.15 ± 22.32 102.55 ± 27.88 < .0001
GGT, gamma-glutamyltransferase.
�Value was presented with mean ± SD.
https://doi.org/10.1371/journal.pone.0245052.t001
PLOS ONE Association between elevated GGT level and risk of gastrointestinal cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0245052 February 5, 2021 4 / 12
metabolic syndrome gradually increased as the GGT quartile level increased. The level of FBG
also increased as the level of GGT quartile increased. The baseline characteristics of included
population according to the GGT quartile level after stratification by sex are shown in S1 and
S2 Tables.
Association between serum GGT level and the risk of gastrointestinal
cancer
During the 8-year follow-up, 3792 cases of esophageal cancer, 57,932 cases of stomach cancer,
and 68,789 cases of colorectal cancer developed. For each type of gastrointestinal cancer, the
number of incident cases, the incidence rate, and the adjusted hazard ratio (HR) according to
the GGT quartile level are shown in Table 2. After adjusting for age, sex, BMI, smoking, drink-
ing, exercise, and income, the risk of gastrointestinal cancer significantly increased with a
gradual rise of the serum GGT level, regardless of the type of cancer. The adjusted HRs for
esophageal cancer incidence for Q2, Q3, and Q4 in comparison with Q1 were 1.218 [95% con-
fidence interval (95%CI), 1.098–1.351], 1.445 [1.305–1.559], and 2.408 [2.184–2.654], respec-
tively (p for trend <0.001). The adjusted HRs for stomach cancer incident for Q2, Q3, and Q4
in comparison with Q1 were 1.012 [0.987–1.037], 1.042 [1.017–1.068], and 1.121 [1.093–
1.149], respectively (p for trend<0.001). Similarly, the adjusted HRs for colorectal cancer inci-
dence for Q2, Q3, and Q4 in comparison with Q1 were 1.030 [1.007–1.054], 1.091 [1.067–
1.116], and 1.185 [1.158–1.212], respectively (p for trend <0.001) (Fig 2).
Association between hyperglycemia and risk of gastrointestinal cancer
For each type of gastrointestinal cancer, the number of incident cases and incidence rates strat-
ified by glycemic status are presented in Table 3. After multivariable adjustment, compared to
the non-DM group, the incidence of each gastrointestinal cancer was higher in both IFG and
DM group (esophagus, HR: 1.198 [1.113–1.290] in the IFG group and 1.278 [1.170–1.397] in
Table 2. Risk of gastrointestinal cancer according to serum GGT quartile level.
GGT quartile P for trend
Cancer site Q1 Q2 Q3 Q4
Esophagus Cases, n 671 780 945 1,396
Incidence rate1 0.46 0.53 0.62 0.97
Model 1, HR (95% CI)2 1� 1.194 (1.077–1.324) 1.403 (1.270–1.549) 2.415 (2.200–2.651) <0.001
Model 2, HR (95% CI)3 1� 1.218 (1.098–1.351) 1.445 (1.305–1.559) 2.408 (2.184–2.654) <0.001
Stomach Cases, n 12,406 13,530 15,470 15,886
Incidence rate1 8.52 9.17 10.15 11.04
Model 1, HR (95% CI)2 1� 1.028 (1.003–1.053) 1.073 (1.048–1.099) 1.172 (1.144–1.200) <0.001
Model 2, HR (95% CI)3 1� 1.012 (0.987–1.037) 1.042 (1.017–1.068) 1.121 (1.093–1.149) <0.001
Colorectal Cases, n 13,749 15,802 18,953 20,265
Incidence rate1 9.45 10.72 12.45 14.09
Model 1, HR (95% CI)2 1� 0.983 (0.918–1.052) 1.075 (1.010–1.145) 1.209 (1.139–1.284) <0.001




2Adjusted for age, sex
3Adjusted for age, sex, BMI, smoking, drinking, exercise, income.
https://doi.org/10.1371/journal.pone.0245052.t002
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the DM group; stomach: 1.050 [1.030–1.071] in the IFG group and 1.181 [1.154–1.210] in the
DM group; and colorectal: 1.089 [1.069–1.108] in the IFG group and 1.217 [1.191–1.244] in
the DM group).
Fig 2. Association between serum GGT quartile level and risk of gastrointestinal cancer. (a) esophageal cancer, (b)
stomach cancer, and (c) colorectal cancer. Q1-4: GGT quartile level.
https://doi.org/10.1371/journal.pone.0245052.g002
Table 3. Risk of gastrointestinal cancer according to glycemic status.
Glycemic status P for trend
Cancer site Non-DM IFG DM
Esophagus Cases, n 1,996 1,122 674
Incidence rate1 0.48 0.87 1.44
Model 1, HR (95% CI)2 1� 1.155 (1.074–1.243) 1.168 (1.070–1.276) <0.001
Model 2, HR (95% CI)3 1� 1.198 (1.113–1.290) 1.278 (1.170–1.397) <0.001
Stomach Cases, n 32,862 18,214 10,951
Incidence rate1 7.93 11.74 20.03
Model 1, HR (95% CI)2 1� 1.056 (1.036–1.077) 1.191 (1.164–1.220) <0.001
Model 2, HR (95% CI)3 1� 1.050 (1.030–1.071) 1.181 (1.154–1.210) <0.001
Colorectal Cases, n 39,604 18,214 10,951
Incidence rate1 9.57 14.14 23.60
Model 1, HR (95% CI)2 1� 1.109 (1.089–1.128) 1.246 (1.220–1.274) <0.001
Model 2, HR (95% CI)3 1� 1.089 (1.069–1.108) 1.217 (1.191–1.244) <0.001
DM, Diabetes mellitus; IFG: Impaired fasting glucose.
�Reference value.
1Per 10,000 person-year
2Adjusted for age, sex
3Adjusted for age, sex, BMI, smoking, drinking, exercise, income.
https://doi.org/10.1371/journal.pone.0245052.t003
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Effect of serum GGT level on the risk of gastrointestinal cancer stratified
by glycemic status
Stratified analyses by glycemic status were conducted to evaluate the interaction of an elevated
GGT level and hyperglycemia contributing to the risk of gastrointestinal cancer. The subjects
were stratified into non-DM, IFG, and DM groups by glycemic status, and each group was
divided into Q4 groups and other groups (Q1–3) in accordance with the serum GGT quartile
level. After setting Q1–3 groups in non-DM as a reference group, the adjusted HR of the inci-
dence in gastrointestinal cancer was estimated for each group (Table 4).
An elevated GGT level had a significant effect on the incidence of esophageal cancer. The
risk of esophageal cancer was higher in the Q4 than Q1–3 groups regardless of glycemic status.
Additionally, the Q4 groups of non-DM and IFG showed a higher risk of esophageal cancer
than the Q1–3 group of DM (non-DM/Q4, HR: 1.98 [95%CI, 1.799–2.180]; IFG/Q4, 2.089
[1.873–2.331]; and DM/Q1-3, 1.168 [1.037–1.316]) (Fig 3A). An elevated serum GGT level
and hyperglycemia showed an interactive effect on the incidence of stomach and colorectal
cancer. For stomach cancer, the Q4 group of DM showed the highest risk (HR: 1.283 [95%CI:
1.237–1.331]), and the HR did not differ between the Q4 group of IFG and the Q1–3 group of
DM (IFG/Q4, HR: 1.129 [95%CI: 1.094–1.165]; and DM/Q1-3, 1.164 [1.130–1.199]) (Fig 3B).
The risk of colorectal cancer was highest in the Q4 group of DM (HR: 1.342 [95%CI: 1.299–
1.386]). In contrast, the HR in the Q4 group of IFG was higher than that in the Q1–3 group of
DM, although not significant (IFG/Q4, HR: 1.214 [95%CI: 1.180–1.248]; and DM/Q1-3, 1.193
[1.161–1.227]) (Fig 3C).
Discussion
In this nationwide population-based study, we demonstrated that an elevated serum GGT
level was significantly associated with the risk of gastrointestinal cancer. In regard to site-spe-
cific cancer incidence, the risks of esophageal, stomach, and colorectal cancers all increased as
the GGT level increased. Moreover, the risk of gastrointestinal cancer was also related to
hyperglycemia including IFG. The stratified analysis of the association between an elevated
GGT level and the risk of gastrointestinal cancer by glycemic status showed that an elevated
GGT level had a dominant effect on incidence of esophageal cancer. Notably, an elevated GGT
level and hyperglycemia showed an interactive effect on the incidence of stomach and colorec-
tal cancers. To the best of our knowledge, this is the first large-scale study to confirm the
Table 4. Association risk of gastrointestinal cancer and serum GGT level stratified by glycemic status.
Glycemic status GGT level Cancer site
Esophagus Stomach Colorectal
Incidence rate1 HR (95% CI)2 Incidence rate1 HR (95% CI)2 Incidence rate1 HR (95% CI)2
Non-DM Q1-Q3 0.41 1� 7.68 1� 9.11 1�
Q4 0.76 1.98 (1.799–2.180) 9.02 1.077 (1.049–1.105) 11.44 1.093 (1.068–1.119)
IFG Q1-Q3 0.77 1.193 (1.088–1.309) 11.71 1.043 (1.019–1.067) 13.61 1.067 (1.044–1.090)
Q4 1.09 2.089 (1.873–2.331) 11.90 1.129 (1.094–1.165) 15.41 1.214 (1.180–1.248)
DM Q1-Q3 1.32 1.168 (1.037–1.316) 21.51 1.164 (1.130–1.199) 24.17 1.193 (1.161–1.227)
Q4 1.60 2.341 (2.063–2.656) 18.01 1.283 (1.237–1.331) 22.85 1.342 (1.299–1.386)
DM: Diabetes Mellitus, IFG: Impaired fasting glucose.
�Reference value.
1Per 10,000 person-year
2Adjusted for age, sex, BMI, smoking, drinking, exercise, income.
https://doi.org/10.1371/journal.pone.0245052.t004
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association of elevated GGT level and hyperglycemia with the risk of gastrointestinal cancer
and to reveal the interaction of the two factors.
Our findings are consistent with previous several epidemiologic studies reporting a signifi-
cant correlation between an elevated GGT level and incidence of gastrointestinal cancer.
Cohort studies from Austria and Sweden revealed that subjects with high serum GGT levels
had an increased risk of gastrointestinal cancer [10, 12, 13], and a meta-analysis found a posi-
tive association between serum GGT levels and the risk of gastrointestinal cancer [15].
Another study in Korea showed that an elevated GGT level was associated with an increased
risk of esophageal, stomach, and colorectal cancers, but this was significant only in men [14].
Although the underlying mechanism for the link between an elevated GGT level and the risk
of gastrointestinal cancer is not completely understood, an elevated serum GGT level may
increase the risk of cancer via the oxidative stress pathway related to glutathione metabolism
[25]. Several preclinical studies identified that increased GGT activity can be a response to oxi-
dative stress and, in turn, the persistent production of reactive oxygen species by increased
GGT activity may cause genetic instability and tumor progression [25–29]. These findings are
the most plausible mechanisms related to the association between an elevated GGT level and
increased risk of gastrointestinal cancer.
Although there was a difference in degree for the specific site of cancer, an elevated GGT
level and hyperglycemia were both related to the increased risk of gastrointestinal cancer and
the risk was highest in the high GGT group of DM patients. Moreover, it is well known that an
elevated GGT level is associated with hyperglycemia because several studies found that an
Fig 3. Effect of an elevated GGT level on the risk of gastrointestinal cancer stratified by glycemic status. (a)
esophageal cancer, (b) stomach cancer, and (c) colorectal cancer. DM: diabetes mellitus IFG: impaired fasting glucose,
Q1-4: GGT quartile level.
https://doi.org/10.1371/journal.pone.0245052.g003
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elevated GGT level may be involved in the development of prediabetes or diabetes [30–32].
There is corroborative evidence to support the correlations between pairs among an elevated
GGT level, hyperglycemia, and carcinogenesis. Insulin resistance is a pivotal mechanism to
develop prediabetes and type 2 DM, and it causes hyperinsulinemia [17]. Although it is still
uncertain, hyperinsulinemia may promote cell proliferation via various pathways and ulti-
mately contribute to the incidence of cancer [33–35]. In addition, increased oxidative stress
may induce insulin resistance and pancreatic β-cell dysfunction [36, 37]. Chronic inflamma-
tion is closely related to both insulin resistance and increased oxidative stress and has been rec-
ognized as a critical factor for carcinogenesis [38, 39]. It is presumed that a series of these
factors interact with one another, affecting the development of cancer. Further studies are
needed to investigate the cause of differences in the interaction between an elevated GGT level
and hyperglycemia according to the type of cancer, and the fundamental mechanism of
carcinogenesis.
It is remarkable that the impact of an elevated GGT level and hyperglycemia on the inci-
dence of gastrointestinal cancer differed with the specific site of cancer. The effect of high
GGT level was overwhelming in developing esophageal cancer. However, the interactive effect
of an elevated GGT level and hyperglycemia, which contributed to the risk of stomach and
colorectal cancer, was indirectly revealed. Considering the higher tendency for colorectal can-
cer risk in patients with high GGT level of the IFG group compared with a low GGT level of
the DM group, the serum GGT level has potential as a discriminating marker in predicting
colorectal cancer, especially in prediabetic patients. Therefore, development of a model is
required to precisely estimate an individual’s risk of developing gastrointestinal cancer based
on serum GGT level and glycemic status.
This was a large-scale cohort study with nearly 8.1 million participants. However, this study
had several limitations. First, it was limited to assessing the effect of lowering the GGT level or
FBG on the incidence of gastrointestinal cancer, because only the baseline levels were col-
lected. Further longitudinal studies are needed to evaluate the change in the incidence of gas-
trointestinal cancer as the level of GGT changes. In addition, the definition of DM in this
study did not include all the diagnostic criteria for DM. Although this definition has been
widely used in previous nationwide studies [40, 41], additional studies with a more reliable def-
inition for DM are required. To dispel concern due to the confounding effect of hepatic dys-
function on the outcomes, we excluded patients with liver cirrhosis or hepatitis. However, the
results for liver function data including of liver enzymes were not adjusted. Finally, the results
on the interaction between an elevated GGT level and glycemic status should be interpreted
cautiously because they were estimated with the indirect statistical method of stratified
analysis.
In conclusion, this large-scale study showed that an elevated GGT level was associated with
an increased risk of gastrointestinal cancer. Additionally, the effect of an elevated GGT level
on the cancer incidence varied with the type of cancer and glycemic status. Further studies are
needed to assess the effect of sequential change in GGT level and glycemic status on the inci-
dence of gastrointestinal cancer. Despite some limitations, this study provides meaningful evi-
dence for clinicians to develop a strategy for screening of gastrointestinal cancer according to
GGT level and glycemic status.
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